BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29985663)

  • 1. Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting.
    Celio L; Fabbroni C
    Expert Opin Pharmacother; 2018 Aug; 19(11):1267-1277. PubMed ID: 29985663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
    Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
    Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
    Navari RM
    Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
    Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
    Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
    Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
    Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
    Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
    Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
    Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
    J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
    Clark-Snow RA; Vidall C; Börjeson S; Jahn P
    Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Kurteva G; Chilingirova N; Rizzi G; Caccia T; Stella V; Bernareggi A
    Eur J Pharm Sci; 2019 Nov; 139():105041. PubMed ID: 31404621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
    Lorusso V; Karthaus M; Aapro M
    Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
    Schwartzberg L; Roeland E; Andric Z; Kowalski D; Radic J; Voisin D; Rizzi G; Navari R; Gralla RJ; Karthaus M
    Ann Oncol; 2018 Jul; 29(7):1535-1540. PubMed ID: 29722791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
    Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
    Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
    Keating GM
    Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
    Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
    Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.